UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

1561/Validation of Russian Versions of Brief Pain Inventory (BPI-R), Brief Fatigue Inventory (BFI-R) and M.D. Anderson Symptom Inventory (MDASI-R) to Assess Symptoms in Cancer Patients

Quality of life research, 2003-11, Vol.12 (7), p.798-798

2003

Link zum Volltext

Verfügbarkeit prüfen

Cyclin D1 and its prognostic value in planning of endocrine therapy for women of postmenopausal age with breast cancer (5 years follow-up)

European journal of cancer (1990), 2018-04, Vol.92, p.S43

2018

Link zum Volltext

Verfügbarkeit prüfen

178 (PB-079) - Cyclin D1 and its prognostic value in planning of endocrine therapy for women of postmenopausal age with breast cancer (5 years follow-up)

European journal of cancer (1990), 2018-04, Vol.92, p.S43-S43

2018

Link zum Volltext

Verfügbarkeit prüfen

Genomic Classification of Cutaneous Melanoma

Cell, 2015-06, Vol.161 (7), p.1681-1696

2015

Link zum Volltext

Verfügbarkeit prüfen

B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study

Frontiers in oncology, 2022-06, Vol.12, p.909505-909505

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

Cancer chemotherapy and pharmacology, 2019-10, Vol.84 (4), p.839-847

2019

Link zum Volltext

Verfügbarkeit prüfen

424 The Role of Cyclin D1 in Planning of Endocrine Therapy for Women of Postmenopausal Age with Breast Cancer

European journal of cancer (1990), 2012-03, Vol.48, p.S170-S170

2012

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

The Lancet (British edition), 2009-05, Vol.373 (9674), p.1525-1531

2009

Link zum Volltext

Verfügbarkeit prüfen

2LBA The first results of using intraoperative radiotherapy in treatment of women with breast cancer on early stages

European journal of cancer (1990), 2014-03, Vol.50, p.S1-S1

2014

Link zum Volltext

Verfügbarkeit prüfen

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

British journal of cancer, 2013-02, Vol.108 (3), p.503-511

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the effectiveness of intraoperative radiotherapy with external beam radiotherapy in patients with early breast cancer

Sibirskiĭ onkologicheskiĭ zhurnal, 2024-03, Vol.23 (1), p.36-44

2024

Link zum Volltext

Verfügbarkeit prüfen

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of oncology, 2014-10, Vol.25 (10), p.1979-1987

2014

Link zum Volltext

Verfügbarkeit prüfen

2MO Final analysis of the phase III randomized clinical trial, comparing HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

Annals of oncology, 2022-11, Vol.33, p.S1431-S1431

2022

Link zum Volltext

Verfügbarkeit prüfen

P4-01-22: Cyclin D1 and Its Prognostic Value in Planning of Endocrine Therapy for Women of Postmenopausal Age with Breast Cancer

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P4-P4-01-22

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S96-S96

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

Investigational new drugs, 2014-02, Vol.32 (1), p.145-153

2014

Link zum Volltext

Verfügbarkeit prüfen

1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study

Annals of oncology, 2020-09, Vol.31, p.S745-S745

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: Real life experience

European journal of cancer (1990), 2020-10, Vol.138, p.S59-S59

2020

Link zum Volltext

Verfügbarkeit prüfen

HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin

European journal of cancer (1990), 2017-02, Vol.72, p.S41-S41

2017

Link zum Volltext

Verfügbarkeit prüfen

190P - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

Annals of oncology, 2019-10, Vol.30, p.v63-v64

2019

Link zum Volltext

Verfügbarkeit prüfen

3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

Annals of oncology, 2019-10, Vol.30, p.v63-v64

2019

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2010-06, Vol.68 (3), p.420-426

2010

Link zum Volltext

Verfügbarkeit prüfen

MICROSATELLITE-UNSTABLE COLORECTAL CANCER IN ELDERLY PATIENTS: CLINICAL FEATURES AND THE ROLE OF IMMUNODEFICIENCY

Sibirskiĭ onkologicheskiĭ zhurnal, 2020-03, Vol.19 (1), p.31-39

2020

Link zum Volltext

Verfügbarkeit prüfen

P137 - Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: real life experience

Breast (Edinburgh), 2019-03, Vol.44, p.S61-S62

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(76)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(35)
Female
(31)
Middle Aged
(25)
Aged
(24)
Adult
(22)
Male
(18)
Treatment Outcome
(14)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Neoplasm Staging
(10)
Breast Neoplasms - Drug Therapy
(8)
Breast Neoplasms - Pathology
(7)
Oncology
(7)
Aged, 80 And Over
(6)
Antineoplastic Agents, Hormonal - Therapeutic Use
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Breast Cancer
(5)
Hematology, Oncology And Palliative Medicine
(5)
Trastuzumab
(5)
Antibodies, Monoclonal, Humanized
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

1561/Validation of Russian Versions of Brief Pain Inventory (BPI-R), Brief Fatigue Inventory (BFI-R) and M.D. Anderson Symptom Inventory (MDASI-R) to Assess Symptoms in Cancer Patients

Cyclin D1 and its prognostic value in planning of endocrine therapy for women of postmenopausal age with breast cancer (5 years follow-up)

178 (PB-079) - Cyclin D1 and its prognostic value in planning of endocrine therapy for women of postmenopausal age with breast cancer (5 years follow-up)

Genomic Classification of Cutaneous Melanoma

B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

424 The Role of Cyclin D1 in Planning of Endocrine Therapy for Women of Postmenopausal Age with Breast Cancer

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

2LBA The first results of using intraoperative radiotherapy in treatment of women with breast cancer on early stages

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

Comparison of the effectiveness of intraoperative radiotherapy with external beam radiotherapy in patients with early breast cancer

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

2MO Final analysis of the phase III randomized clinical trial, comparing HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

P4-01-22: Cyclin D1 and Its Prognostic Value in Planning of Endocrine Therapy for Women of Postmenopausal Age with Breast Cancer

Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study

Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: Real life experience

HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin

190P - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

MICROSATELLITE-UNSTABLE COLORECTAL CANCER IN ELDERLY PATIENTS: CLINICAL FEATURES AND THE ROLE OF IMMUNODEFICIENCY

P137 - Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: real life experience

Suchergebnisse filtern